[go: up one dir, main page]

MY108716A - New isobutyl-substituted methanesulphonyl-quinolyl- mehtoxyphenyl- cycloalkylacetamides. - Google Patents

New isobutyl-substituted methanesulphonyl-quinolyl- mehtoxyphenyl- cycloalkylacetamides.

Info

Publication number
MY108716A
MY108716A MYPI93001599A MYPI19931599A MY108716A MY 108716 A MY108716 A MY 108716A MY PI93001599 A MYPI93001599 A MY PI93001599A MY PI19931599 A MYPI19931599 A MY PI19931599A MY 108716 A MY108716 A MY 108716A
Authority
MY
Malaysia
Prior art keywords
substituted
cycloalkylacetamides
methanesulphonyl
isobutyl
mehtoxyphenyl
Prior art date
Application number
MYPI93001599A
Inventor
Klaus-Helmut Mohrs Dr
Michael Matzke Dr
Siegfried Raddatz Dr
Fruchtmann Romanis
Armin Hatzelmann Dr
Dr Reiner Muller-Peddinghaus Prof
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MY108716A publication Critical patent/MY108716A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

THE NEW ISOBUTYL-SUBSTITUTED METHANESULPHONYLQUINOLYL-METHOXYPHENYL-CYCLOALKYLACETAMIDES CAN BE PREPARED BY REACTION OF THE CORRESPONDING RACEMIC OR ENANTIOMERIC ACIDS WITH METHANESULPHONAMIDE, IT BEING POSSIBLE TO RESOLVE THE RACEMIC FINAL PRODUCTS INTO ENANTIOMERS BY CUSTOMARY METHODS. THE ISOBUTYL-SUBSTITUTED METHANESULPHONYL-QUINOLYLMETHOXYPHENYL-CYCLOACETAMIDES CAN BE EMPLOYED AS ACTIVE COMPOUNDS IN MEDICAMENTS.
MYPI93001599A 1992-08-12 1993-08-11 New isobutyl-substituted methanesulphonyl-quinolyl- mehtoxyphenyl- cycloalkylacetamides. MY108716A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4226649A DE4226649A1 (en) 1992-08-12 1992-08-12 New isobutyl-substituted methanesulfonyl-quinolylmethoxyphenyl-cycloalkylacetic acid aminols

Publications (1)

Publication Number Publication Date
MY108716A true MY108716A (en) 1996-11-30

Family

ID=6465373

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI93001599A MY108716A (en) 1992-08-12 1993-08-11 New isobutyl-substituted methanesulphonyl-quinolyl- mehtoxyphenyl- cycloalkylacetamides.

Country Status (19)

Country Link
EP (1) EP0582916A1 (en)
JP (1) JPH06157462A (en)
KR (1) KR940003937A (en)
CN (1) CN1039998C (en)
AU (1) AU669913B2 (en)
CA (1) CA2103600A1 (en)
CZ (1) CZ282341B6 (en)
DE (1) DE4226649A1 (en)
FI (1) FI933529A7 (en)
HU (1) HUT70171A (en)
IL (1) IL106623A0 (en)
MX (1) MX9304608A (en)
MY (1) MY108716A (en)
NO (1) NO179948C (en)
NZ (1) NZ248350A (en)
PL (1) PL174102B1 (en)
RU (1) RU2103261C1 (en)
SK (1) SK86693A3 (en)
ZA (1) ZA935828B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4443892A1 (en) * 1994-12-09 1996-06-13 Bayer Ag 4- (Quinolin-2-yl-methoxy) phenyl acetic acid derivatives
DE4443891A1 (en) 1994-12-09 1996-06-13 Bayer Ag Heterocyclically substituted oxy-phenyl- (phenyl) glycinolamides
US5931170A (en) * 1998-10-08 1999-08-03 Addway Engineering Limited Dental flosser
US6441176B1 (en) * 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814504A1 (en) * 1988-04-29 1989-11-09 Bayer Ag (ALPHA) -SUBSTITUTED 4- (CHINOLIN-2-YL-METHOXY) PHENYL ACETIC ACIDS AND SITES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICAMENTS
DE3900261A1 (en) * 1988-05-31 1989-12-07 Bayer Ag SUBSTITUTED 4- (CHINOLIN-2-YL-METHOXY) PHENYL-ACETIC ACID DERIVATIVES
DE3916663A1 (en) * 1989-05-23 1990-11-29 Bayer Ag SUBSTITUTED (CHINOLIN-2-YL-METHOXY) PHENYL-ACYL-SULPHONAMIDES AND CYANAMIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS
DE4105551A1 (en) * 1991-02-22 1992-08-27 Bayer Ag 2-SUBSTITUTED CHINOLINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINAL PRODUCTS
DE4112533A1 (en) * 1991-04-17 1992-10-22 Bayer Ag METHOD FOR THE PRODUCTION OF ENANTIOMER-PURE SUBSTITUTED (CHINOLIN-2-YL-METHOXY) PHENYL ACETIC ACIDS

Also Published As

Publication number Publication date
ZA935828B (en) 1994-03-10
NO932731L (en) 1994-02-14
DE4226649A1 (en) 1994-02-17
IL106623A0 (en) 1993-12-08
AU4425593A (en) 1994-02-17
KR940003937A (en) 1994-03-14
CZ282341B6 (en) 1997-07-16
CN1039998C (en) 1998-09-30
AU669913B2 (en) 1996-06-27
EP0582916A1 (en) 1994-02-16
FI933529L (en) 1994-02-13
SK86693A3 (en) 1994-09-07
NO179948C (en) 1997-01-15
RU2103261C1 (en) 1998-01-27
PL300025A1 (en) 1994-03-21
FI933529A0 (en) 1993-08-10
NO932731D0 (en) 1993-07-29
PL174102B1 (en) 1998-06-30
HUT70171A (en) 1995-09-28
CA2103600A1 (en) 1994-02-13
HU9302320D0 (en) 1993-10-28
JPH06157462A (en) 1994-06-03
CZ163693A3 (en) 1994-03-16
NO179948B (en) 1996-10-07
FI933529A7 (en) 1994-02-13
MX9304608A (en) 1994-02-28
NZ248350A (en) 1994-12-22
CN1087084A (en) 1994-05-25

Similar Documents

Publication Publication Date Title
AU2993892A (en) Novel azaheterocyclylmethyl-chromans
AU8581991A (en) Mercaptoacetylamide derivatives as inhibitors of enkephalinase and ACE, and processes for their production
EP0606899A3 (en) Processes for production of optically active 4-halo-3-hydroxybutyric acid esters.
HUT52070A (en) Herbicide compositions containing pyrimidinyl-benzoic acid derivatives as active components, and process for producing the active components
FI892016A0 (en) Process for the preparation of new therapeutically useful, optionally substituted 4 - (- quinolin-2-ylmethoxy) -phenylacetic acids and esters
FR2626288B1 (en)
WO1990009993A3 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
NZ513569A (en) Process for the preparation of (2R)-2-propyloctanoic acid
PL298890A1 (en) Sulfonylobenzyl substituted benzo- and pyridopyridones, method of obtaining sames and therapeutic agents containing them
ES8207584A1 (en) Process for the enzymatic preparation of L-2-amino-4-methyl-phosphino-butyric acid.
MY108716A (en) New isobutyl-substituted methanesulphonyl-quinolyl- mehtoxyphenyl- cycloalkylacetamides.
TW207995B (en)
AU4113797A (en) Method of preparing (s) - or (r) -3,3,3-trifluoro-2-hydroxy-2- methylpropionic acid
AU583155B2 (en) Process for the manufacture of iodine.
AU5643686A (en) Novel carboxylic acid esters, methods for production thereof and insecticides containing them as the active ingredient
YU60778A (en) Process for the enzymatic hydrolysis of racemic hydantoin into optically active amino-acids
EP0997534A3 (en) Process for the resolution of racemic arylalkylcarboxylic acid esters
AU2732388A (en) A process for the enzymatic hydrolysis of alpha- aminoadipinyl-monoamino compounds
TW245713B (en)
EP0207636A3 (en) Process for producing optically active dichloropropanol using microorganism
MX9603342A (en) Piranes-4h-substituted.
AU2911389A (en) 1-aralkyl-2-mercaptoimidazolines as dopamine-beta-hydroxylase inhibitors
AU7772287A (en) Separation of diastereomers
NZ239435A (en) Conversion of the r(-) isomer of ketoprofen to the s(+) isomer
AU3495089A (en) Process for the racemization of optically active d-2-n-phenacetylamino-4-methylphosphinobutyric acid